“Anthropic $2 Trillion IPO, Apple's "Crackgate," & Retatrutide Results”
AI summary · The speaker is long LLY with about $15,000, bought from $877 on March 29, 2026 and averaged; the position is up 38% versus the S&P's about 12% this year. He also notes LLY's upcoming GLP-1 drug beat Ozempic head-to-head.
Eli Lilly's upcoming GLP-1 drug has just outperformed Ozembeek in a head-to-head contest.